Summary
Behavioural and some neurochemical effects of Ro 40-7592 (3,4-dihydroxy-4′-methyl-5-nitrobenzophenone), a new COMT inhibitor, were studied in rats and mice. Ro 40-7592 increased the effect of L-DOPA (plus benserazide) on locomotor activity, reserpine-induced hypothermia, and catalepsy induced by pimozide, haloperidol and fluphenazine. Locomotor hyperactivity induced by amphetamine or nomifensine, as well as stereotypy induced by amphetamine (but not apomorphine), were also increased by Ro 40-7592. The drug stimulated exploratory activity in the open field test. It decreased the levels of HVA and 3-MT, increased the level of DOPAC but did not change the levels of dopamine in the striatum, nucleus accumbens and frontal cortex. These results indicate that Ro 40-7592 may improve the therapy with L-DOPA (plus decarboxylase inhibitor) of Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv Chim Acta 72: 952–968
Colzi A, Zürcher G, Da Prada M (1989) Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitor Ro 41-0960. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson's disease. Springer, Wien New York, pp 191–196
Delini-Stula A, Morpurgo C (1968) Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in rats. Int J Neuropharmacol 7: 391–394
Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27: 135–206
Janssen PAJ, Jagenau AHM, Schellekens KHL (1960) Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenylpiperidino)-butyrophenone, part IV. Influence of haloperidol (R 1625) and of chlorpromazine on the behaviour of rats in an unfamiliar “open field” situation. Psychopharmacologia (Berlin) 1: 389–392
Lindén I-B, Nissinen E, Etemadzadeh E, Kaakkola S, Männistö P, Pohto P (1988) Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J Pharmacol Exp Ther 247: 289–293
Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease. Trends Pharmacol Sci 10: 54–56
Männistö PT, Kaakkola S, Nissinen E, Lindén I-B, Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43: 1465–1471
Muggli D, Zuercher G, Da Prada M (1989) Inhibition of COMT by Ro 40-7592, a potential drug for Parkinson's disease therapy. 12th Annual Meeting ENA, Torino, September 3–7, 1989
Nissinen E, Lindén I-B, Schultz E, Kaakkola S, Männistö PT, Pohto P (1988) Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rats. Eur J Pharmacol 153: 263–269
Reches A, Mielke LR, Fahn S (1982) 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887–888
Zürcher G, Keller HH, Bruderer H, Borgulya J, Da Prada M (1988) Caratteristiche neurochimiche di una nuova classe di inhibitori della COMT attivi per via orale: livelli plasmatici di DOPA e 3-OMD nel ratto trattato con DOPA e benserazide. In: Agnoli A, Battistin L (eds) Morbi di Parkinson e demenze: metodologie diagnostiche. Pubbl D Guanella, Roma, pp. 15–29
Zürcher G, Colzi A, Da Prada M (1989a) Marked improvement of DOPA bioavailability in rats by Ro 40-7592, a novel, orally active COMT inhibitor. International Basal Ganglia Society, Third Triennial Meeting, Capo Boi, Cagliari, June 10–13, 1989
Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1989b) Ro 40-7592, a novel, very potent and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. In: Parkinsons disease: anatomy, pathology and therapy (Adv Neurol 53: 497–502)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maj, J., Rogóż, Z., Skuza, G. et al. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm Gen Sect 2, 101–112 (1990). https://doi.org/10.1007/BF02260898
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260898